+Compare
EVO
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
4.13B

EVO Evotec SE Forecast, Technical & Fundamental Analysis

GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for EVO with price predictions
08:00 PM EDT Jun 01, 2023

EVO in upward trend: 10-day moving average broke above 50-day moving average on May 16, 2023

The 10-day moving average for EVO crossed bullishly above the 50-day moving average on May 16, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 01, 2023. You may want to consider a long position or call options on EVO as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EVO just turned positive on May 10, 2023. Looking at past instances where EVO's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

EVO moved above its 50-day moving average on May 10, 2023 date and that indicates a change from a downward trend to an upward trend.

The 50-day moving average for EVO moved above the 200-day moving average on May 15, 2023. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in of 166 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EVO broke above its upper Bollinger Band on June 02, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for EVO entered a downward trend on May 15, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.253) is normal, around the industry mean (42.346). EVO's P/E Ratio (476.190) is considerably higher than the industry average of (53.681). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.722). EVO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.026). P/S Ratio (5.131) is also within normal values, averaging (55.313).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Intra-Cellular Therapies (NASDAQ:ITCI), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.32B. The market cap for tickers in the group ranges from 246 to 79.43B. ZTS holds the highest valuation in this group at 79.43B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 25%. INLB experienced the highest price growth at 83%, while ABTI experienced the biggest fall at -59%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was -17% and the average quarterly volume growth was -98%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 72
Price Growth Rating: 65
SMR Rating: 85
Profit Risk Rating: 93
Seasonality Score: -1 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

EVO is expected to report earnings to fall 318.52% to 2 cents per share on August 09

Evotec SE EVO Stock Earnings Reports
Q2'23
Est.
$0.02
Q1'23
Beat
by $0.01
Q4'22
Missed
by $0.03
Q3'22
Est.
$-0.14
Q2'22
Beat
by $0.01
The last earnings report on May 12 showed earnings per share of -1 cents, beating the estimate of -1 cents. With 16.51K shares outstanding, the current market capitalization sits at 4.13B.
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
N/A
Address
Essener Bogen 7
Phone
+49 40560810
Employees
4952
Web
https://www.evotec.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ADIV13.560.22
+1.64%
SmartETFs Asia Pcfc Dvdnd Bldr ETF
GVIP82.110.95
+1.17%
Goldman Sachs Hedge Industry VIP ETF
FLRN30.51N/A
N/A
SPDR® Blmbg Inv Grd Flt Rt ETF
DIAL17.58-0.01
-0.06%
Columbia Diversified Fixed Inc Allc ETF
DFHY20.73-0.09
-0.41%
Donoghue Forlines Tactical HY ETF

EVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVO has been loosely correlated with ZTS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then ZTS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
+4.38%
ZTS - EVO
46%
Loosely correlated
+3.54%
PETQ - EVO
46%
Loosely correlated
+3.34%
EBS - EVO
43%
Loosely correlated
+0.49%
ELAN - EVO
43%
Loosely correlated
+7.21%
SNDL - EVO
42%
Loosely correlated
+2.07%
More

Groups containing EVO

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
+4.38%
Pharmaceuticals
(undefined stocks)
-1%
Poorly correlated
+1.39%
Pharmaceuticals: Other
(undefined stocks)
-1%
Poorly correlated
+1.33%